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Microarray Analysis of Gene Expression Profiles
in Cells Transfected With Nonviral Vectors
Sarah A Plautz1, Gina Boanca1, Jean-Jack M Riethoven2 and Angela K Pannier1
Department of Biological Systems Engineering, University of Nebraska-Lincoln, Lincoln, Nebraska, USA; 2Bioinformatics Core Research Facility,
University of Nebraska-Lincoln, Lincoln, Nebraska, USA
1

Inefficient gene delivery is a critical factor limiting the
use of nonviral methods in therapeutic applications
including gene therapy and tissue engineering. There
have been few efforts to understand or engineer the
molecular signaling pathways that dictate the efficacy
of gene transfer. Microarray analysis was used to determine endogenous gene expression profiles modulated
during nonviral gene transfer. Nonviral DNA lipoplexes
were delivered to HEK 293T cells. Flow cytometry was
used to isolate a population of transfected cells. Expression patterns were compared between transfected and
nontransfected samples, which revealed three genes
that were significantly upregulated in transfected cells,
including RAP1A, a GTPase implicated in integrin-mediated cell adhesion, and HSP70B′, a stress-inducible gene
that may be important for maintaining cell viability.
Furthermore, RAP1A was also significantly upregulated
in untransfected cells that were exposed to lipoplexes
but that had not expressed the transgene as compared
to control, untreated cells. Transfection in the presence
of activators of upregulated genes was enhanced, demonstrating the principle of altering endogenous gene
expression profiles to enhance transfection. With a
greater understanding of signaling pathways involved in
gene delivery, more efficient nonviral delivery schemes
capitalizing on endogenous factors can be developed to
advance therapeutic applications.
Received 9 February 2011; accepted 9 May 2011; published online
9 August 2011. doi:10.1038/mt.2011.161

Introduction
Gene delivery approaches provide a mechanism to directly alter
gene expression within a cell population, with tremendous potential in basic science (e.g., to study gene expression), therapeutics
(e.g., gene therapy to correct genetic deficiencies or treat acquired
disease), and tissue engineering (e.g., to present factors in scaffolds that guide tissue formation). Nonviral delivery techniques
are less efficient than viral systems, but offer the advantages of
low toxicity and immunogenicity, lack of pathogenicity, and ease
of production with greater control and flexibility, making these
vectors attractive alternatives to viruses. Typical nonviral gene

delivery systems involve the ionic/electrostatic complexation of
DNA with cationic polymers (polyplexes)1 or lipids (lipoplexes).2
Complexation protects DNA against degradation by nucleases and
serum components and enhances cellular uptake by reducing the
effective size of DNA and promoting interactions between positively charged DNA complexes and the negatively charged cellular
membrane. These complexation agents also can facilitate intracellular trafficking, while dissociating from the DNA to allow expression.3,4 However, even with complexation strategies as described
above, both extracellular5 and intracellular6 barriers exist that prevent efficient nonviral gene transfer. Extracellular barriers to gene
delivery include mass transport limitations, cytotoxicity, degradation, and aggregation,5 as well as cell targeting. Once a complex
reaches a target cell, intracellular barriers to gene transfer include
cell binding, cell entry, release from endosomal compartments,
cytosolic transit, nuclear entry,7 and subsequently expression of
the transgene.6
To date, most efforts to understand and improve the efficiency
of nonviral gene delivery have focused on altering the physicochemical properties of delivery systems and developing new delivery strategies, focusing on the physical and chemical characteristics
of the cationic vector8–10 or examining the effect of complexing
agents on subcellular localization/distribution,11 intracellular trafficking and pharmacokinetics,12–14 and transfection efficiency of
DNA complexes, providing only a fragmented understanding of
that process because of the differences in techniques and study
variables, without regard to the underlying cellular states or signaling pathways. Even with these efforts, nonviral gene delivery
remains inefficient and its mechanisms largely unknown because
of the complexity of the process. The lack of direct information
on the endogenous gene expression profiles and intracellular signaling pathways that might be controlling transfection efficiency
limits the optimal design of delivery vectors.
Microarray analysis has been performed to investigate the toxicogenomics of nonviral vectors used for gene delivery.15–18 However
in these previous studies, the objective was to treat the cells with
cationic polymer or lipid (often in the absence of complexation
with DNA) to observe the associated gene expression profiles and
cellular responses, in particular cytotoxicity. In these studies, there
was no isolation of transfected cells from untransfected, rather cell
populations treated with vector alone or vector complexed with
DNA were compared to untreated conditions. In most studies,
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apoptosis was observed and confirmed with gene expression profiles, which should not be unexpected as nonviral vectors are typically more toxic when not complexed with DNA.19
While these previous studies have used microarray analysis
to explore global gene expression profiles for pharmacological
and toxicological studies of lipids and polymers used in nonviral gene delivery, there have been few efforts to understand the
molecular signaling pathways that dictate efficient gene transfer.
In this report, gene expression profiles of an isolated population of
successfully transfected cells were investigated using microarray
analysis and related to cellular mechanisms that might be responsible for successful gene transfer. Upregulation of two identified
genes was confirmed with transfection studies performed in the
presence and absence of activators of these genes. With a greater
understanding of key signaling pathways involved in gene delivery afforded by the analysis reported here, the mechanisms that
render cells responsive to DNA transfer will be determined, which
can be used to develop more efficient nonviral delivery schemes.

Results
Microarray analysis was used to identify how endogenous gene
expression profiles are modulated during nonviral gene transfer.
Nonviral DNA complexes (composed of cationic lipids complexed
with plasmid DNA encoding for green fluorescent protein, GFP)
were delivered to HEK 293T human embryonic kidney epithelial
cells, a widely used cell line in transfection experiments (Figure 1).

Plasmid DNA
(pCMV-LUC/GFP)

Cationic lipid
(Lipofectamine 2000)

Transfection conditions were optimized for both high transfection efficiency and low cytotoxicity (Supplementary Figure S1).
Flow cytometry was then used to sort GFP+ cells from GFP−
cells, allowing isolation of a population of transfected cells and a
population of cells that had been exposed to complexes, but not
transfected, respectively (Figure 1 and Supplementary Figure
S2). Expression patterns were compared between GFP+ and GFP−
samples (six versus three replicates), which revealed three genes
that were statistically differentially expressed between the two
samples (twofold or greater change in expression, false discovery
rate (FDR) adjusted P < 0.05, Table 1). These three genes that were
substantially upregulated in the GFP+ (transfected cells) as compared to GFP− (untransfected cells), include RAP1A, a GTPase
implicated in a variety of cell behaviors including integrin-mediated cell adhesion; HSP70B′, a stress-inducible gene that encodes
for a heat shock protein that may be important for maintaining
cell viability; and PVT1, a non-protein coding oncogene.
Expression patterns were compared between GFP− and
Control samples (three versus six replicates) to determine genes
which may be upregulated in cells that have been exposed to DNA
complexes, but that were not expressing GFP at the time when
cells were sorted and RNA was isolated. RAP1A was the only gene
to be upregulated, with a substantial fold change in expression
(FDR adjusted P < 0.05, Table 2).
Finally, expression patterns were compared between GFP+
and Control samples (six replicates each), which revealed 19 genes

DNA complex
(DNA:lipid ratio of 1:1.5)

HEK 293T cells

Transfection assayed at
24 hours and GFP+ cells
sorted with flow cytometry

GFP+

GFP−

Control

RNA extraction
Microarray analysis: Affymetrix GeneChip Human Genome U133 Plus 2.0
arrays analyzed via Affymetrix GeneChip Operating Software (GCOS)

Figure 1 Schematic of experimental design. Cell transfection, sorting of transfected cells (GFP+) from untransfected cells (GFP−) cells using flow
cytometry, as well as Control cell population, RNA extraction and microarray analysis used to generate gene expression profiles.
Table 1 Genes upregulated in transfected cells (GFP+) as compared to untransfected cells (GFP−)
Representative public ID

Gene title

Fold change

NM_002155/X51757

Gene symbol

HSPA6

Heat shock 70 kd protein 6 (HSP70B′)

10.332/2.966a

AB051846

RAP1A

RAP1A, member of RAS oncogene family

9.172

BG200951

PVT1

Pvt1 oncogene (non-protein coding)

2.507

Abbreviation: GFP, green fluorescent protein.
Upregulation greater than twofold and FDR adjusted P < 0.05.
a
Two fold changes are reported as this gene is located at two distinct probes on microarray.
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Table 2 Genes upregulated in untransfected cells (GFP−) as compared to Control cells
Representative public ID

Gene symbol

Gene title

Fold change

AB051846

RAP1A

RAP1A, member of RAS oncogene family

59.162

AB051846

RAP1A

RAP1A, member of RAS oncogene family

110.187

Abbreviation: GFP, green fluorescent protein.
Upregulation greater than twofold and FDR adjusted P < 0.05.

Table 3 Genes upregulated in transfected cells (GFP+) as compared to Control cells
Representative public ID

Gene symbol

Gene title

Fold change

AB051846

RAP1A

RAP1A, member of RAS oncogene Family

542.631

AB051846

RAP1A

RAP1A, member of RAS oncogene family

1016.865

NM_002155/X51757

HSPA6

Heat shock 70 kd protein 6 (HSP70B′)

12.001/3.773a

X65232/AA284829

ZNF79

Zinc finger protein 79

2.261/3.026a

NM_001674/AB066566

ATF3

Activating transcription factor 3

3.775/3.328a

NM_002394

SLC3A2

Solute carrier family 3 (activators of dibasic and neutral amino
acid transport), member 2

2.121

BG538800

ZNF473

Zinc finger protein 473

2.004

BG200951

PVT1

Pvt1 oncogene (non-protein coding)

2.514

BE788667

PRR14

Proline rich 14

2.772

BC000487/NM_012230

POMZP3 /// ZP3

POM (POM121 homolog, rat) and ZP3 fusion /// zona pellucida
glycoprotein 3 (sperm receptor)

NM_000107

DDB2

Damage-specific DNA binding protein 2, 48 kd

2.521

NM_006145/BG537255

DNAJB1

DnaJ (Hsp40) homolog, subfamily B, member 1

2.2/2.293a

BC002426

PEA15

Phosphoprotein enriched in astrocytes 15

AF003934

GDF15 /// LOC100292463 Growth differentiation factor 15 /// similar to growth
differentiation factor 15

U83981/NM_014330

PPP1R15A

Protein phosphatase 1, regulatory (inhibitor) subunit 15A

NM_002133

HMOX1

Heme oxygenase (decycling)1

3.179

NM_001613

ACTA2

Actin, α-2, smooth muscle, aorta

2.116

AW592227

KHDRBS1

KH domain containing, RNA binding, signal transduction associated 1

2.015

BF340083

SLC1A4

Solute carrier family 1(glutamate/neutral amino acid transporter), member 4

2.554

2.532/2.664a

2.047
2.576
2.003/2.291a

Abbreviation: GFP, green fluorescent protein.
Upregulation greater than twofold and FDR adjusted P < 0.05.
a
Two fold changes are reported as this gene is located at two distinct probes on microarray.

that were statistically differentially expressed between the two
samples (twofold or greater change in expression, FDR adjusted
P < 0.05, Table 3), including the three genes identified as upregulated between GFP+ and GFP− (RAP1A, HSP70B′, and PVT1), as
expected. In addition to RAP1A, there were other genes upregulated in GFP+ cells with a link to integrin activation and cell
adhesion (Table 3), including two members of the solute carrier
family of proteins, solute carrier family 3 (activators of dibasic and
neutral amino acid transport), member 2 (LOC442497/SLC3A2/
CD98) and solute carrier family 1 (glutamate/neutral amino acid
transporter), member 4 (SLC1A4). In addition to upregulation
of HSP70B′, the DnaJ (Hsp40) homolog, subfamily B, member 1
gene was also shown to be upregulated in GFP+ cells as compared
to Control cells (Table 3), and like HSP70B′, Hsp40 plays a role in
a variety of cell functions related to cell stress. Other upregulated
genes of interest include several potentially involved in apoptosis,
including the activating transcription factor 3 (ATF3), a transcription factor that may activate or repress transcription to allow cells
to adapt to various responses, including apoptosis; the damage2146

specific DNA binding protein 2 (DDB2), which facilitates the
cellular response to DNA damage; the phosphoprotein enriched
in astrocytes 15 gene (PEA15), which is a death effector domaincontaining protein, and thus could be implicated in apoptosis;
and the protein phosphatase 1, regulatory (inhibitor) subunit 15A
gene (PPP1R15A), which is a member of a group of genes whose
transcript levels are increased following stressful growth arrest
conditions and treatment with DNA-damaging agents. The actin,
α-2 (ACTA2) gene, a component of the cytoskeleton, was also
upregulated.
As RAP1A and HSP70B′ were both approximately tenfold
upregulated in GFP+ cells as compared to GFP− cells, as well as
substantially upregulated in GFP+ cells as compared to Control
cells (and RAP1A was also upregulated in GFP− as compared
to Control cells) their upregulation was confirmed by quantitative real-time PCR, probing for expression of both RAP1A and
HSP70B′ in GFP+, GFP−, and Control cells (Figure 2). These two
genes were also further studied in transfection experiments, in the
presence and absence of pharmacological activators of these two
www.moleculartherapy.org vol. 19 no. 12 dec. 2011
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Figure 2 Verification of gene expression profiles. Real-time PCR was
performed to verify microarray results for (a) RAP1A and (b) HSP70B′.
Data normalized to 18S endogenous control and reported as mean with
SEM.

genes to determine if their modulation prior to DNA complex delivery might affect transfection efficiency. These transfection studies
were performed in HEK 293T cells and NIH/3T3 mouse fibroblast
cells. The fibroblast cells were used to determine if the genes identified as upregulated in HEK 293T cells might be global regulators of gene transfer (i.e., affect transfection profiles in another
cell type). For either cell type, cells were seeded, treatments were
applied for a period of time, and then media was removed and
replaced with fresh media containing DNA-lipid complexes. For
RAP1A,
8-(4-Chlorophenylthio)-2′-O-methyladenosine-3′,5′cyclic monophosphate sodium salt (8CPT-2Me-cAMP, referred to
as CPT), a cAMP analog that has been shown to specifically activate EPAC in a variety of cell lines, including HEK 293 cells, was
added.20 EPAC is a cAMP-activated guanine-nucleotide exchange
factor and thus regulator of RAP1A.20 For HSP70B′, the gene was
activated by placing cells at 42.5 °C for 1 hour and allowing them
to recover at 37 °C for 6 hours,21 a technique which has been shown
to upregulate HSP70B′ expression levels in human epithelial cell
lines. Standard transfection in the presence of vehicle alone was
used as a control. Activation of RAP1A and HSP70B′ in both HEK
293T and NIH/3T3 cells (Figures 3 and 4) resulted in approximately twofold enhancement of transfection.

Discussion
Recently, the fields of “toxicogenomics” and “polymer genomics” have begun to investigate pharmacogenomic responses to
synthetic polymers and nanomaterials used to deliver genes or
drugs into cells, with a focus on cell toxicity and associated gene
expression changes that control the cellular response to various
drugs and genes.22 Most studies utilize gene expression profiles
Molecular Therapy vol. 19 no. 12 dec. 2011

Figure 3 RAP1A activation and DNA delivery. Transfection in (a) HEK
293T and (b) NIH/3T3 cells in with activator of Rap1a (CPT), compared
to standard transfection conditions with vehicle. Transfection is reported
as relative light units (RLU) per protein amount, represented as mean
with SEM. Number in parentheses represents fold changes over standard
transfection.

obtained by microarray technology, which allows for the accurate representation of the cellular response to delivery vectors.18
For instance, treatment of human A431 epithelial cells with cationic lipids altered expression of 27 genes involved in cell proliferation, differentiation, and apoptosis,15 confirmed by apoptosis
assays. However, in that study cells were merely treated with the
cationic lipid without complexation first with DNA, and thus the
results correlate to properties of the vector itself, and not transfection. Transcriptional effects of lipid-mediated transfection were
explored in MCF-7 cells, and gene expression profiling revealed
that the transfection reagents caused off-target effects and these
effects were not attributed to expression of the transgene itself, but
like in most reported studies, transfected cells were not isolated
prior to RNA extraction for analysis.23 However, several genes and
gene families identified in that study correlate with genes shown to
be differentially expressed in this current study, identified between
GFP+ and control samples (Table 3), including ATF3, HMOX1,
PPP1R15A, and DNAJB1, as well as members of the heat shock
family of proteins and the solute carrier gene family. Cationic
polymers have also been examined for their toxicogenomic effect
on cells, including polyethylenimine16 and dendrimers.17 In these
studies, there was no isolation of transfected cells from untransfected, rather just treated versus untreated using polymer alone
or polymers complexed with DNA. Gene expression changed
2147
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Figure 4 HSP70B′ activation and DNA delivery. Transfection in
(a) HEK 293T and (b) NIH/3T3 cells that were heat-shocked compared
to standard transfection conditions. Transfection is reported as relative
light units (RLUs) per protein amount, represented as mean with SEM.
Number in parentheses represents fold changes over standard transfection. (**P <0.01).

in ~10% of the genes16 and cationic-dendrimer–induced gene
changes in cells were increased upon complexation with small
interfering RNA molecules,17 suggesting the presence of the dendrimer might help determine the level of gene silencing by small
interfering RNAs. Microarray analysis was also used to study local
tissue response after delivery of a polymeric gene delivery system
in vivo.18 Specifically, the toxicological profile of polyethylenimine, chitosan, and their complexes with DNA was determined
in the mouse lung after administration of these complexes. Genes
involved in stress reactions were induced by polyethylenimine,
but also genes that stabilized the reporter protein luciferase and
other proteins, but again, profiles were not determined on pure
populations of transfected cells. These previous studies highlight
not only the importance of understanding cellular responses to
gene delivery agents, but also the importance of studying an isolated population of transfected cells to identify genes that may be
responsible for successful gene transfer.

Upregulation of genes involved in integrin
activation and cell adhesion
In this current study, gene expression profiles of successfully
transfected cells provide molecular evidence for some findings
in the literature on nonviral delivery mechanisms, including the
role of integrin activation and cell adhesion. The RAP1A gene was
2148

determined to be upregulated in transfected cells (GFP+) as compared to untransfected cells (GFP−) (Table 1), as well as upregulated in untransfected cells (GFP−) as compared to control cells
(Table 2), and highly upregulated in transfected cells (GFP+) as
compared to control cells (Table 3). As stated above, RAP1A is a
Ras-like GTPase implicated in growth modulation, differentiation,
and integrin-mediated cell adhesion.24 RAP1A-mediated adhesion and spreading has been demonstrated in several cell types,
including fibroblasts25 and endothelial cells.26 RAP1A appears
to modulate cell adhesion and spreading through the Rho family of GTPases, with RAC1 required downstream of RAP1A for
cell spreading. Overexpression of RAP1A has been shown to activate integrins and inhibition of RAP1A inhibits integrins,27 which
has been shown to block cell adhesion to various substrates. The
overexpression of RAP1A in GFP+ cells indicates that it may play
a role in nonviral gene delivery; furthermore its upregulation in
GFP− cells suggests that RAP1A expression may also be important
for internalization of DNA complexes.
In addition to RAP1A, there were other genes upregulated
in transfected cells (GFP+) as compared to Control cells with a
link to integrin activation and cell adhesion (Table 3), including
LOC442497/SLC3A2/CD98 and SLC1A4. In particular, SLC3A2
(CD98) is a type II membrane glycoprotein expressed in all cell
types, with the exception of platelets, and is a major contributor
to the integrin-dependent activation of RAC.28 CD98 has been
shown to promote activity of α5β1 integrin in fibroblast cultures
and cells deficient in this gene are markedly defective in integrindependent cell spreading and migration.29
The upregulation of genes involved in integrin activation and
cell adhesion explain studies that link the presence of extracellular
matrix molecules to nonviral gene transfer. The addition of fibronectin to lipoplexes, for example, enhanced transfection efficiency in
prostate tumor cells,30 most likely by exposing the integrin binding
site in fibronectin available upon fibronectin binding to lipoplexes,
and thus enhancing the association of the DNA complexes with the
cells. Fibronectin or collagen I addition to DNA calcium phosphate
particles resulted in high transgene expression in mammalian
cells, presumably since these particles could be recognized by the
integrin receptors for subsequent internalization.31 Extracellular
matrix molecules have also been shown to enhance transfection
in substrate-mediated gene delivery strategies,32–35 where plasmid
DNA or DNA complexes are immobilized to a surface or biomaterial that supports cell adhesion, thereby placing the DNA directly
in the cellular microenvironment,36 most likely by promoting cell
adhesion and the DNA polyplex internalization process.

Upregulation of genes involved in stress
response (heat shock)
The heat shock 70 kd protein 6 gene (HSPA6) was found to be
upregulated in transfected cells (GFP+) as compared to untransfected cells (GFP−) (Table 1). The heat shock protein 70 family is
a group of chaperones involved in protein folding, stabilization,
and shuttling functions through the cell. Members of this family
can be induced by various cellular stresses.37 HSP70B′, a member
of the family, is strictly inducible, having no detectable levels of
expression in most cells,38 and may be important for maintaining
cell viability37 and cytoprotection.21 In addition, the DnaJ (Hsp40)
www.moleculartherapy.org vol. 19 no. 12 dec. 2011
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homolog, subfamily B, member 1 gene was also shown to be
upregulated in transfected cells (GFP+) as compared to Control
cells (Table 3), and like HSP70B′, plays a role in a variety of cell
functions and has been shown to enhance nuclear localization of
viral particles.39
The upregulation of genes involved in stress response indicate
that a cell’s ability to respond to stress could control transfection
efficiency. Thus, expression of the HSP70B′ gene may be important for maintaining cell viability37 during transfection. A related
member of the family, hsp70, was also shown to be upregulated in
human A431 epithelial cells in response to treatment with cationic
lipids.15 In addition to protecting the cells from the stress of treatment with DNA complexes, HSP70B′ and DnaJ have also been
shown to be involved in nuclear import of viral particles39,40 and
thus could potentially be involved with nuclear entry of nonviral
gene delivery complexes, in particular those with plasmids containing viral promoters, thereby improving transfection levels.

Upregulation of genes involved in apoptosis
Several genes with potential roles in apoptosis were found to be
upregulated in transfected cells (GFP+) as compared to Control
cells (Table 3), including the activating transcription factor 3
(ATF3) gene. ATF3 induction may activate or repress transcription to allow cells to adapt to various stresses and stimuli, including induction of apoptosis.41 Typically expressed in low levels,
ATF3 is a stress-inducible gene.42 While ATF3 has been shown to
be a key regulator in cell stress response, whether its expression
is a protective response or if it is part of the cellular response that
leads to detrimental outcomes seems to be dependent on the cell
type and nature of the stimulus. These dual roles have now led to
the characterization of ATF3 as an “adaptive response” gene that
participates in cellular processes to adapt to extra- or intracellular
changes.41 In addition to ATF3, other genes with putative roles in
apoptosis were identified as upregulated in GFP+ cells as compared to Control cells (Table 3), including DDB2, PEA15, and
PPP1R15A. Given the toxicity of lipid-DNA complexes, it is not
surprising that some apoptotic genes were revealed in the studies reported here. These results further highlight the need for less
toxic nonviral delivery systems.
Transfection in presence of activators
of Rap1a and HSP70B′
While the major objective of this paper was to examine gene
expression profiles of transfected cells to identify candidate genes
for future studies into the molecular mechanisms of gene delivery, initial transfection experiments, in the presence and absence
of activators of RAP1A and HSP70B′, further implicate the role
of these genes in nonviral gene delivery and demonstrate an
approach to enhancing transfection through priming of the cells
through molecular factors, without any changes to the cationic
vector. Most attempts to alter transfection profiles have focused
on modification of vectors, as opposed to molecular modification
of cells. While treatment with CPT and heat shock, reported here,
were likely not specific modulators of RAP1A and HSP70B′ gene
expression, respectively, these data serve to demonstrate the principle of altering endogenous gene expression profiles to enhance
transfection, and suggest that a cell’s ability to respond to stress
Molecular Therapy vol. 19 no. 12 dec. 2011
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and adhesion factors may determine the efficacy of gene transfer. Furthermore, given that activation strategies employed here
were likely not specific to RAP1A or HSP70B′, it might be anticipated that molecular approaches to modulate these genes prior
to DNA delivery could result in an even greater enhancement in
transfection.
The use of gene delivery in therapeutic applications, including gene therapy to treat genetic deficiencies or tissue engineering
matrices for the treatment of organ loss and failure, has remained
limited due to challenges with current delivery systems. The lack of
direct information on the endogenous gene expression profiles and
intracellular signaling pathways that might be controlling transfection efficiency limits the optimal design of delivery vectors.
This study is the first to examine the effect of transfection on basal
cell signaling, to understand the molecular basis for efficient gene
transfer, and to then in turn use that information to reveal as methods to prime cells for delivery. Further work is needed to assess the
effects of different delivery agents, different cell types, earlier time
points, and molecular interventions on gene expression profiles of
transfected cells. However, with a greater understanding of endogenous gene expression profiles of transfected cells, more efficient
nonviral delivery schemes capitalizing on endogenous factors can
be developed to advance therapeutic applications.

Materials and Methods
Cell culture. HEK 293T cells (ATCC, Manassas, VA), a human embryonic
epithelial kidney cell line that is widely used for transfection studies, were
cultured in T-75 flasks in Dulbecco’s modified Eagle’s medium (Gibco/
Invitrogen, Carlsbad, CA) containing 4.5 g/l glucose, supplemented with
10% fetal bovine serum (Gibco), 2 mmol/l l-glutamine (Gibco), and 100
units/ml of penicillin (Gibco) and maintained at 37 °C in a humidified 5%
CO2 atmosphere. For seeding, cells were dissociated with 1 mmol/l EDTA
and counted using a hemocytometer and trypan blue staining for viable
cells. Cells were then seeded at a density of 3.4 × 106 cells/flask into T-75
flasks for transfection, in order to generate enough transfected cells to
be collected through sorting (see below) for RNA extraction. Additional
flasks were seeded for control conditions. NIH/3T3 mouse fibroblast cells
(ATCC) were cultured at 37 °C and 5% CO2 in Dulbecco’s modified Eagle’s
medium (ATCC) supplemented with 10% calf serum (Colorado Serum
Company, Denver, CO) and 1% penicillin-streptomycin (Gibco). For
transfection studies in the presence/absence of activators, cells were seeded
into wells of a 48-well plate (HEK 293T: 22,800 cells/well and NIH/3T3:
15,000 cells/well) 18 hours prior to activator treatment and subsequent
transfection.
Transfection for microarray analysis. Plasmid pEGFP-LUC, which
encodes for both the enhanced green fluorescent protein (EGFP) and
firefly luciferase protein (LUC) under the direction of a CMV promoter (Clontech, Mountain View, CA), and was used for all transfection experiments. Plasmids were purified from bacteria culture using
Qiagen (Valencia, CA) reagents and stored in Tris–EDTA buffer solution (10 mmol/l Tris, 1 mmol/l EDTA, pH 7.4) at −20 °C. DNA complexes
were formed with Lipofectamine 2000 (LF2000; Invitrogen), following
manufacturer’s instructions. Briefly, DNA complexes were formed at a
DNA:lipid ratio of 1:1.5 (µg of DNA to µl of LF2000) in serum-free, OptiMEM media (Invitrogen) by adding transfection reagent diluted in media
dropwise to DNA in media, mixing by gentle pipetting, and incubating for
20 minutes. After an 18-hour period to allow HEK 293T cells to adhere
(seeded into flasks as described above), DNA complexes (11.25 μg DNA
per flask) were added into the media above the cells. Note, these complex
conditions (lipid to DNA ratio and DNA amount) were selected based on
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an exhaustive optimization of transfection conditions in which ratio and
DNA amounts were compared to (i) transfection efficiency (percentage of
EGFP-positive cells assayed by fluorescence microscopy using Leica DMI
3000B, Bannockburn, IL); and (ii) cell viability and morphology (analyzed
through phase microscopy using Leica DMI 3000B) (Supplementary
Figure S1). Thus, the above complexation condition represents that with
the highest transfection efficiency levels (~40%) and lowest cytotoxicity
(Supplementary Figure S1a,d,e) after 24 hours. Transfection experiments
for microarray analysis were performed in triplicate on three separate days,
with some GFP+ and control conditions performed up to six times.
Cell sorting and RNA extraction. Transfected cells (GFP+) were isolated
from untransfected cells (GFP−) 24 hours after addition of the DNA complexes using flow cytometry (Figure 1). Briefly, cells were removed from
the flask substrate, counted, and concentrated for subsequent sorting, using
a B-D FACSVantage SE three-laser, high speed cell sorter in the University
of Nebraska-Lincoln’s Center for Biotechnology Flow Cytometry Core
Facility. Cells were sorted based on forward and side scattered gate in the
presence or absence of fluorescence (Supplementary Figure S2). A separate set of flasks of cells that were never exposed to DNA complexes were
also dissociated, counted, and sorted through flow cytometry. These cells
are referred to as the Control cells. After obtaining pure populations of
transfected (GFP+) cells, untransfected (GFP−) cells, and control cells,
total RNA was extracted using TRIzol reagent following the manufacturer’s instructions (Invitrogen) and further purified using Qiagen RNeasy
column (Qiagen) with a final dilution in DEPC-treated water. All RNA
samples were quality assessed on a RNA 6000 Nano LabChip using Agilent
BioAnalyzer 2100 (Agilent Technologies, Santa Clara, CA).
Microarray analysis. Fifteen Affymetrix GeneChip Human Genome U133

Plus 2.0 Arrays (Affymetrix, Santa Clara, CA) were used for the analysis
of expression of 39,000 human genes in GFP+ (six arrays for six separate
transfection studies), GFP− (three arrays for triplicate studies on untransfected cells that were exposed to DNA complexes), and Control (six arrays
for six separate control conditions) HEK 293T cells. All microarray analysis, as described, was performed at University of Nebraska-Lincoln’s Center
for Biotechnology Genomics and Bioinformatics Core Research Facilities.
Five to ten micrograms of total RNA was used to synthesize cDNA using
an Affymetrix One-Cycle cDNA Synthesis Kit according to the manufacturer’s instructions. All sample preparations followed prescribed protocols (Affymetrix Genechip Expression Analysis Technical manual).
Hybridization was performed at 45 °C overnight on the Affymetrix
Human Genome Array, stained with streptavidin-phycoerythrin conjugate on an Affymetrix Fluidics Station 450, which was followed by
scanning with the GeneChip Scanner 3000 7G (Affymetrix). Affymetrix
GeneChip Operating Software (GCOS v1.3) was used for washing, scanning, and basic data analysis. This included calculation of absolute values
and normalization of the data with respect to internal standards. These
microarray data were then normalized using methods described by Wu
et al., 2004.43 Differentially expressed genes between replicates of each
of the three conditions (GFP+, GFP−, and Control) were determined
using the linear models for microarrays package in R/Bioconductor, with
Benjamini-Hochberg adjusted P values.44 Genes that were twofold up- or
downregulated and had a False Discovery Rate adjusted P value of 0.05
or less were deemed to be significant. The gene expression data has been
deposited at the NCBI Gene Expression Omnibus with series number
GSE20615.

Quantitative real-time PCR. Quantitative real-time PCR was used to con-

firm upregulation of the two genes, RAP1A and HSP70B′. For these studies,
cells were transfected in T-75 flasks, sorted using flow cytometry and RNA
extracted, as described above. Total RNA (1 µg)was treated with DNase I
(Promega, Madison, WI) to remove any genomic DNA and reverse transcribed to cDNA using M-MLV reverse transcriptase (Promega) and random primers (Promega). Gene specific primers were designed for RAP1A,
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5′-TGGATACTGCAGGGACAGAGCAAT-3′ (forward), 5′-ACATCTTCC
GTGTCCTTAACCCGT-3′ (reverse) and HSP70B′, 5′-TGCAAGAGGAA
AGCCTTAGGGACA-3′ (forward), 5′-ACAGATTTGCTCCAGCTCCCT
CTT-3′ (reverse). Real-time PCR was performed using Sybr Green and an ABI
7300 System (Applied Biosystems, Carlsbad, CA). Data was normalized to an
endogenous control, 18S, using the following primers 5′-CGGCTACCACAT
CCAAGGAA-3′ (forward), 5′-GCTGGAATTACCGCGGCT-3′ (reverse).
Transfection in presence of gene activators. Transfections were performed in the presence of activators of two identified genes, RAP1A and
HSP70B′. For either gene, treatments were applied for a period of time,
then media was removed and replaced with fresh media containing DNAlipid complexes formed at 1:1.5 ratio (0.15 µg DNA per well), as described
above. For RAP1A, 8-(4-Chlorophenylthio)-2′-O-methyladenosine-3′,5′cyclic monophosphate sodium salt (8CPT-2Me-cAMP; Tocris Bioscience,
Ellisville, MO) was added at 20 µmol/l20 for 15 minutes, a concentration
demonstrated to activate RAP1A without cytotoxicity (data not shown).
For HSP70B′, the gene was activated by placing cells at 42.5 °C for 1 hour,
allowing them to recover at 37 °C for 6 hours,21 and then viability was
monitored before proceeding with transfection. Standard transfection
in the presence of vehicle alone was used as a control. After 24 hours,
transfection levels were quantified by measuring the luciferase activity
using the Luciferase Assay System (Promega), for which cells were lysed
and assayed for enzymatic activity using a luminometer (Turner Designs,
Sunnyvale, CA), and luciferase activity (RLUs) was normalized to the total
protein amount determined with the BCA protein assay (Pierce, Rockford,
IL). Each transfection experiment was performed in triplicate wells on
duplicate days. Statistical analysis was performed using Prism software
(GraphPad Prism 5, LaJolla, CA). Comparative analyses were completed
using student t-test at a 95% confidence level. Mean values with SEM are
reported.

SUPPLEMENTARY MATERIAL
Figure S1. Optimization of transfection efficiency.
Figure S2. Sorting of transfected cells.
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